Peer-reviewed Publications
Clinical Cancer Research
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Journal of Medical Virology
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor
Journal of Medical Virology onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25501
Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
Int. J. Mol. Sci. 2019, 20, 621; doi:10.3390/ijms20030621
Optimization of Early Steps in Oncolytic Adenovirus.
ONCOS-401 Production in T-175 and HYPERFlasks
ONCOIMMUNOLOGY https://doi.org/10.1080/2162402X.2018.1532763
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
J Med Virol. 2018;1–5. https://doi.org/10.1002/jmv.25229
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model
Cancer Gene Therapy https://doi.org/10.1038/s41417-018-0038-x
Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401
PLoS ONE 12(8): e0182715. https://doi.org/10.1371/journal.pone.0182715
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
International Journal of Cancer 2016 Jun 10. doi: 10.1002/ijc.30228
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model
Journal for ImmunoTherapy of Cancer (Vol 4, Issue 17, 2016)
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers
Human Gene Therapy (Vol 26, Issue 8, 2015)
Replication-competent viruses as cancer immunotherapeutics: emerging clinical data
OncoImmunology (Vol 4, Issue 7, 2015)
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
OncoImmunology (Vol 3, Issue 10, 2014)
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization